<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">lvrach</journal-id><journal-title-group><journal-title xml:lang="ru">Лечащий Врач</journal-title><trans-title-group xml:lang="en"><trans-title>Lechaschi Vrach</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1560-5175</issn><issn pub-type="epub">2687-1181</issn><publisher><publisher-name></publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.51793/OS.2025.28.10.015</article-id><article-id custom-type="elpub" pub-id-type="custom">lvrach-1481</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>АКТУАЛЬНАЯ ТЕМА</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>TOPICAL THEME</subject></subj-group></article-categories><title-group><article-title>Цинк-зависимая модуляция эффективности ботулинического токсина типа А: стратегии преодоления вариабельности терапевтического ответа в инъекционной косметологии</article-title><trans-title-group xml:lang="en"><trans-title>Zinc-dependent modulation of botulinum toxin type A efficacy: strategies for overcoming variability in therapeutic response in injection cosmetology</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0005-4494-0170</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Михайлова</surname><given-names>Н. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Mikhaylova</surname><given-names>N. P.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Михайлова Наталья Павловна, к.м.н., старший научный сотрудник</p><p>111123, Москва, 2-я Владимирская ул., 12, корп. 3</p></bio><bio xml:lang="en"><p>Natalia P. Mikhaylova, cand. of sci. (Med.), Senior Researcher</p><p>12 bld 3, 2nd Vladimirskaya str., Moscow, 111123</p></bio><email xlink:type="simple">mikhailova@martinex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0004-3475-9979</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Эйдельман</surname><given-names>Л. Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Eidelman</surname><given-names>L. R.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Эйдельман Луиза Расуловна, медицинский советник</p><p>127473, Москва, 2-й Волконский переулок, 10</p></bio><bio xml:lang="en"><p>Luiza R. Eidelman, medical advisor</p><p>10 2nd Volkonsky lane, Moscow, 127473</p></bio><email xlink:type="simple">l.r.eidelman@microgen.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0001-3227-4415</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Знатдинов</surname><given-names>Д. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Znatdinov</surname><given-names>D. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Знатдинов Дамир Ильдусович, научный сотрудник</p><p>111123, Москва, 2-я Владимирская ул., 12, корп. 3</p></bio><bio xml:lang="en"><p>Damir I. Znatdinov, researcher</p><p>12 bld 3, 2nd Vladimirskaya str., Moscow, 111123</p></bio><email xlink:type="simple">znatdinov@martinex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0001-9384-176X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Илешина</surname><given-names>Т. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Ileshina</surname><given-names>T. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Илешина Татьяна Викторовна, к.м.н., доцент кафедры косметологии и дермато-венерологии</p><p>121359, ул. Маршала Тимошенко, 19, с. 1А</p></bio><bio xml:lang="en"><p>Tatyana V. Ileshina, cand. of sci. (Med.), Associate Professor, Department of dermatovenerology and cosmetology</p><p>19 bld 1A Marshala Timoshenko str., Moscow, 121359</p></bio><email xlink:type="simple">info@cgma.su</email><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Международный научно-исследовательский центр инновационных технологий «Мартинекс»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Martinex International Research Center for Innovative Technologies</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Научно-производственное объединение «Микроген»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Scientific and Production Association Microgen</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Центральная государственная медицинская академия Управления делами Президента Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Central State Medical Academy of Department of Presidential Affairs</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>31</day><month>10</month><year>2025</year></pub-date><volume>0</volume><issue>10</issue><fpage>98</fpage><lpage>103</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Михайлова Н.П., Эйдельман Л.Р., Знатдинов Д.И., Илешина Т.В., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Михайлова Н.П., Эйдельман Л.Р., Знатдинов Д.И., Илешина Т.В.</copyright-holder><copyright-holder xml:lang="en">Mikhaylova N.P., Eidelman L.R., Znatdinov D.I., Ileshina T.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://journal.lvrach.ru/jour/article/view/1481">https://journal.lvrach.ru/jour/article/view/1481</self-uri><abstract><sec><title>Введение</title><p>Введение. С момента появления ботулинический токсин типа А стал неотъемлемым инструментом эстетической медицины, позволяющим не только устранять мимические морщины, но и восстанавливать симметрию, корректировать форму лица за счет гармоничного перераспределения мышечного тонуса. Учитывая темпы современной жизни и желание пациентов сохранять ежедневную социальную активность, возрастает необходимость оптимизации результатов и увеличения продолжительности действия ботулинотерапии. Среди возможных решений, способных повлиять на эффективность нейромодуляторов, особый интерес представляет устранение локального дефицита цинка. Выступая незаменимым кофактором легкой цепи ботулотоксина типа А, цинк не только стабилизирует структуру токсина, но и динамически поддерживает его протеазную активность в пресинаптических нейронах. Локальный дефицит этого элемента может стать скрытым барьером достижения оптимального эстетического результата. Современные исследования раскрывают двойственную роль цинка: помимо прямого влияния на каталитический домен ботулинического токсина типа А, он регулирует множество других процессов, опосредованно определяющих скорость элиминации токсина и устойчивость эффекта. Однако традиционные методы коррекции дефицита, такие как пероральная суплементация, демонстрируют противоречивые результаты, что свидетельствует о необходимости инновационных решений.</p></sec><sec><title>Результаты</title><p>Результаты. В данной статье систематизированы данные о молекулярных механизмах цинк-зависимости ботулинического токсина типа А, факторах, способствующих тканевому дефициту микроэлемента, и современных стратегиях его коррекции. Особое внимание уделено клиническим маркерам скрытого дефицита цинка, актуальным для повседневной практики, и перспективам комбинированных подходов, объединяющих высокоочищенные препараты ботулинического токсина типа А с адъювантными методами доставки цинка. Результаты анализа помогут пересмотреть парадигму подготовки пациентов к ботулинотерапии, сделав коррекцию локального дефицита цинка важным этапом повышения эффективности и пролонгации эстетического результата. Для врачей-косметологов понимание этих взаимосвязей становится ключом к преодолению резистентности, сокращению частоты повторных процедур и достижению устойчивой удовлетворенности пациентов – важнейших критериев успеха в современной эстетической медицине.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Background</title><p>Background. Since its introduction, botulinum toxin type A has become an indispensable tool in aesthetic medicine, allowing not only the elimination of expression lines, but also the restoration of symmetry and correction of facial contours through the harmonious redistribution of muscle tone. Given the pace of modern life and patients' desire to maintain daily social activity, there is a growing need to optimize results and increase the duration of botulinum therapy. Among the possible solutions that could affect the effectiveness of neuromodulators, the elimination of local zinc deficiency is of particular interest. Zinc, acting as an indispensable cofactor of the light chain of botulinum toxin type A, not only stabilizes the structure of the toxin, but also dynamically supports its protease activity in presynaptic neurons. A local deficiency of this element can become a «hidden barrier» to achieving optimal aesthetic results. Recent studies reveal the dual role of zinc: in addition to its direct effect on the catalytic domain of BTA, it regulates many other processes that indirectly determine the rate of toxin elimination and the duration of the effect. However, traditional methods of correcting deficiency, such as oral supplementation, show conflicting results, highlighting the need for innovative solutions.</p></sec><sec><title>Results</title><p>Results. This article systematizes data on the molecular mechanisms of zinc dependence of botulinum toxin type A, factors contributing to tissue deficiency of this trace element, and modern strategies for its correction. Particular attention is paid to clinical markers of hidden zinc deficiency relevant to everyday practice and the prospects for combined approaches combining highly purified botulinum toxin type A preparations with adjuvant zinc delivery methods. The results of the analysis are intended to revise the paradigm of preparing patients for botulinum therapy, making the correction of local zinc deficiency an important step in increasing the effectiveness and prolonging the aesthetic result. For cosmetic doctors, understanding these relationships is key to overcoming resistance, reducing the frequency of repeat procedures, and achieving lasting patient satisfaction-the most important criteria for success in modern aesthetic medicine.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>ботулотоксин типа А</kwd><kwd>пролонгированный эффект</kwd><kwd>цинк</kwd><kwd>биодоступность</kwd></kwd-group><kwd-group xml:lang="en"><kwd>botulinum toxin type A</kwd><kwd>prolonged effect</kwd><kwd>zinc</kwd><kwd>bioavailability</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Scott A. B. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology 1980; 87 (10): 1044-1049. https://doi.org/10.1016/s0161-6420(80)35127-0.</mixed-citation><mixed-citation xml:lang="en">Scott A. B. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology 1980; 87 (10): 1044-1049. https://doi.org/10.1016/s0161-6420(80)35127-0.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Артеменко А. Р., Абрамов В. Г. Ботулинический токсин типа A (Релатокс) в лечении хронической мигрени у взрослых: результаты мульти-центрового простого слепого рандомизированного сравнительного исследования IIIb фазы. Журнал неврологии и психиатрии им. С. С. Корсакова. 2023; 123 (5): 89-99.</mixed-citation><mixed-citation xml:lang="en">Artemenko A. R., Abramov V. G. Botulinum toxin type A (Relatox) in the treatment of chronic migraine in adults: results of phase IIIb, randomized, one-blind, multicenter, active-controlled, parallel-group trial. Zhurnal nevrologii i psikhiatrii im. S. S. Korsakova. 2023; 123 (5): 89-99. (In Russ.) https://doi.org/10.17116/jnevro202312305189.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Мингазова Л. Р., Орлова О. Р., Сойхер М. Г., Сойхер М. И., Артеменко А. Р. Миофасциальные орофациальные боли: клинико-патогенетические механизмы, возможности ботулинотерапии. Российский журнал боли. 2025; 23 (2): 12-23.</mixed-citation><mixed-citation xml:lang="en">Mingazova L. R., Orlova O. R., Soykher M. G., Soykher M. I., Artemenko A. R. Myofascial orofacial pain: clinical and pathogenetic mechanisms, possibilities of botulinum therapy. Rossiiskii zhurnal boli. 2025; 23 (2): 12-23. (In Russ.) https://doi.org/10.17116/pain20252302112.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Rasetti-Escargueil C., Palea S. Embracing the Versatility of Botulinum Neurotoxins in Conventional and New Therapeutic Applications. Toxins (Basel). 2024; 16 (6): 261. DOI: 10.3390/toxins16060261. PMID: 38922155; PMCID: PMC11209287.</mixed-citation><mixed-citation xml:lang="en">Rasetti-Escargueil C., Palea S. Embracing the Versatility of Botulinum Neurotoxins in Conventional and New Therapeutic Applications. Toxins (Basel). 2024; 16 (6): 261. DOI: 10.3390/toxins16060261. PMID: 38922155; PMCID: PMC11209287.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Fan Y., Guo X., Tian Y., Li J., Xi H. Botulinum toxin type A inhibits the formation of hypertrophic scar through the JAK2/STAT3 pathway. Biomol Biomed. 2024; 25 (1): 249-258. DOI: 10.17305/bb.2024.10906. PMID: 39132968; PMCID: PMC11647250.</mixed-citation><mixed-citation xml:lang="en">Fan Y., Guo X., Tian Y., Li J., Xi H. Botulinum toxin type A inhibits the formation of hypertrophic scar through the JAK2/STAT3 pathway. Biomol Biomed. 2024; 25 (1): 249-258. DOI: 10.17305/bb.2024.10906. PMID: 39132968; PMCID: PMC11647250.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Fabi S. G., Carruthers J., Joseph J., Cox S. E., Yoelin S., Few J., Kaufman-Janette J., Dayan S. High-Dose Neuromodulators: A Roundtable on Making Sense of the Data in Real-World Clinical Practice. Aesthet Surg J Open Forum. 2021; 3 (4): ojab036. DOI: 10.1093/asjof/ojab036. PMID: 34708202; PMCID: PMC8545706.</mixed-citation><mixed-citation xml:lang="en">Fabi S. G., Carruthers J., Joseph J., Cox S. E., Yoelin S., Few J., Kaufman-Janette J., Dayan S. High-Dose Neuromodulators: A Roundtable on Making Sense of the Data in Real-World Clinical Practice. Aesthet Surg J Open Forum. 2021; 3 (4): ojab036. DOI: 10.1093/asjof/ojab036. PMID: 34708202; PMCID: PMC8545706.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Philipp-Dormston W. G., Joseph J. H., Carruthers J. D. A., Fezza J. P., Mukherjee M., Yasin A., Musumeci M. Why Dosing Matters: A Closer Look at the Dose-Response Relationship With OnabotulinumtoxinA. J Cosmet Dermatol. 2025; 24 (4): e70170. DOI: 10.1111/jocd.70170. PMID: 40285447; PMCID: PMC12032540.</mixed-citation><mixed-citation xml:lang="en">Philipp-Dormston W. G., Joseph J. H., Carruthers J. D. A., Fezza J. P., Mukherjee M., Yasin A., Musumeci M. Why Dosing Matters: A Closer Look at the Dose-Response Relationship With OnabotulinumtoxinA. J Cosmet Dermatol. 2025; 24 (4): e70170. DOI: 10.1111/jocd.70170. PMID: 40285447; PMCID: PMC12032540.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Lebeda F. J., et al. The zinc-dependent protease activity of the botulinum neurotoxins. Toxins. 2010; 2 (5): 978-997. DOI: 10.3390/toxins2050978.</mixed-citation><mixed-citation xml:lang="en">Lebeda F. J., et al. The zinc-dependent protease activity of the botulinum neurotoxins. Toxins. 2010; 2 (5): 978-997. DOI: 10.3390/toxins2050978.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Kogan S., Sood A., Garnick M. S. Zinc and Wound Healing: A Review of Zinc Physiology and Clinical Applications. Wounds. 2017; 29 (4): 102-106.</mixed-citation><mixed-citation xml:lang="en">Kogan S., Sood A., Garnick M. S. Zinc and Wound Healing: A Review of Zinc Physiology and Clinical Applications. Wounds. 2017; 29 (4): 102-106.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Mocchegiani E., Romeo J., Malavolta M., et al. Zinc: dietary intake and impact of supplementation on immune function in elderly. Age (Dordr). 2013; 35 (3): 839-860. DOI: 10.1007/s11357-011-9377-3.</mixed-citation><mixed-citation xml:lang="en">Mocchegiani E., Romeo J., Malavolta M., et al. Zinc: dietary intake and impact of supplementation on immune function in elderly. Age (Dordr). 2013; 35 (3): 839-860. DOI: 10.1007/s11357-011-9377-3.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Hara T., Yoshigai E., Ohashi T., Fukada T. Zinc transporters as potential therapeutic targets: An updated review. J Pharmacol Sci. 2022; 148 (2): 221-228. DOI: 10.1016/j.jphs.2021.11.007.</mixed-citation><mixed-citation xml:lang="en">Hara T., Yoshigai E., Ohashi T., Fukada T. Zinc transporters as potential therapeutic targets: An updated review. J Pharmacol Sci. 2022; 148 (2): 221-228. DOI: 10.1016/j.jphs.2021.11.007.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Maywald M., Rink L. Zinc Deficiency and Zinc Supplementation in Allergic Diseases. Biomolecules. 2024; 14 (7): 863. Published 2024 Jul 19. DOI: 10.3390/biom14070863.</mixed-citation><mixed-citation xml:lang="en">Maywald M., Rink L. Zinc Deficiency and Zinc Supplementation in Allergic Diseases. Biomolecules. 2024; 14 (7): 863. Published 2024 Jul 19. DOI: 10.3390/biom14070863.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Stiles L. I., Ferrao K., Mehta K. J. Role of zinc in health and disease. Clin Exp Med. 2024; 24 (1): 38. Published 2024 Feb 17. DOI: 10.1007/s10238-024-01302-6.</mixed-citation><mixed-citation xml:lang="en">Stiles L. I., Ferrao K., Mehta K. J. Role of zinc in health and disease. Clin Exp Med. 2024; 24 (1): 38. Published 2024 Feb 17. DOI: 10.1007/s10238-024-01302-6.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Gupta S., Brazier A. K. M., Lowe N. M. Zinc deficiency in low- and middle-income countries: prevalence and approaches for mitigation. J Hum Nutr Diet. 2020; 33 (5): 624-643. DOI: 10.1111/jhn.12791.</mixed-citation><mixed-citation xml:lang="en">Gupta S., Brazier A. K. M., Lowe N. M. Zinc deficiency in low- and middle-income countries: prevalence and approaches for mitigation. J Hum Nutr Diet. 2020; 33 (5): 624-643. DOI: 10.1111/jhn.12791.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Schoofs H., et al. Zinc Toxicity: Understanding the Limits. Molecules (Basel, Switzerland). 2024; 13 (29): 3130. DOI: 10.3390/molecules29133130.</mixed-citation><mixed-citation xml:lang="en">Schoofs H., et al. Zinc Toxicity: Understanding the Limits. Molecules (Basel, Switzerland). 2024; 13 (29): 3130. DOI: 10.3390/molecules29133130.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Lansdown A. B. G., et al. Zinc in wound healing: theoretical, experimental, and clinical aspects. Wound repair and regeneration: official publication of the Wound Healing Society [and] the European Tissue Repair Society. 2007; 1 (15): 2-16. DOI: 10.1111/j.1524-475X.2006.00179.x.</mixed-citation><mixed-citation xml:lang="en">Lansdown A. B. G., et al. Zinc in wound healing: theoretical, experimental, and clinical aspects. Wound repair and regeneration: official publication of the Wound Healing Society [and] the European Tissue Repair Society. 2007; 1 (15): 2-16. DOI: 10.1111/j.1524-475X.2006.00179.x.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Saper R. B., Rash R. Zinc: an essential micronutrient. American family physicianvol. 2009; 9 (79): 768-772.</mixed-citation><mixed-citation xml:lang="en">Saper R. B., Rash R. Zinc: an essential micronutrient. American family physicianvol. 2009; 9 (79): 768-772.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">King J. C., et al. Zinc homeostasis in humans. The Journal of nutrition. 2000: 5S (130): 1360S-1366S. DOI: 10.1093/jn/130.5.1360S.</mixed-citation><mixed-citation xml:lang="en">King J. C., et al. Zinc homeostasis in humans. The Journal of nutrition. 2000: 5S (130): 1360S-1366S. DOI: 10.1093/jn/130.5.1360S.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Massih Y. N., Hall A. G., Suh J., King J. C. Zinc Supplements Taken with Food Increase Essential Fatty Acid Desaturation Indices in Adult Men Compared with Zinc Taken in the Fasted State. The Journal of nutrition. 2021; 151 (9): 2583-2589. https://doi.org/10.1093/jn/nxab149.</mixed-citation><mixed-citation xml:lang="en">Massih Y. N., Hall A. G., Suh J., King J. C. Zinc Supplements Taken with Food Increase Essential Fatty Acid Desaturation Indices in Adult Men Compared with Zinc Taken in the Fasted State. The Journal of nutrition. 2021; 151 (9): 2583-2589. https://doi.org/10.1093/jn/nxab149.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Hall A. G., King J. C. The Molecular Basis for Zinc Bioavailability. Int J Mol Sci. 2023; 24 (7): 6561. DOI: 10.3390/ijms24076561. PMID: 37047530; PMCID: PMC10095312.</mixed-citation><mixed-citation xml:lang="en">Hall A. G., King J. C. The Molecular Basis for Zinc Bioavailability. Int J Mol Sci. 2023; 24 (7): 6561. DOI: 10.3390/ijms24076561. PMID: 37047530; PMCID: PMC10095312.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Blasiak J., et al. Zinc and Autophagy in Age-Related Macular Degeneration. International journal of molecular sciences. 2020; 21 (14): 4994. DOI: 10.3390/ijms21144994.</mixed-citation><mixed-citation xml:lang="en">Blasiak J., et al. Zinc and Autophagy in Age-Related Macular Degeneration. International journal of molecular sciences. 2020; 21 (14): 4994. DOI: 10.3390/ijms21144994.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Sanna A., et al. Zinc Status and Autoimmunity: A Systematic Review and Meta-Analysis. Nutrients. 2018; 1 (10): 68. DOI: 10.3390/nu10010068.</mixed-citation><mixed-citation xml:lang="en">Sanna A., et al. Zinc Status and Autoimmunity: A Systematic Review and Meta-Analysis. Nutrients. 2018; 1 (10): 68. DOI: 10.3390/nu10010068.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Foster L., et al. Zinc in Dermatology: Exploring Its Emerging Role in Enhancing Botulinum Toxin Formulations and Clinical Efficacy. Current issues in molecular biology. 2024; 11 (46): 12088-12098. DOI: 10.3390/cimb46110717.</mixed-citation><mixed-citation xml:lang="en">Foster L., et al. Zinc in Dermatology: Exploring Its Emerging Role in Enhancing Botulinum Toxin Formulations and Clinical Efficacy. Current issues in molecular biology. 2024; 11 (46): 12088-12098. DOI: 10.3390/cimb46110717.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Shemais N., et al. The effect of botulinum toxin A in patients with excessive gingival display with and without zinc supplementation: randomized clinical trial. Clinical oral investigations. 2021; 11 (25): 6403-6417. DOI: 10.1007/s00784-021-03944-2.</mixed-citation><mixed-citation xml:lang="en">Shemais N., et al. The effect of botulinum toxin A in patients with excessive gingival display with and without zinc supplementation: randomized clinical trial. Clinical oral investigations. 2021; 11 (25): 6403-6417. DOI: 10.1007/s00784-021-03944-2.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Cohen J. L. Scientific skepticism and new discoveries: an analysis of a report of zinc/phytase supplementation and the efficacy of botulinum toxins in treating cosmetic facial rhytides, hemifacial spasm and benign essential blepharospasm. Journal of cosmetic and laser therapy: official publication of the European Society for Laser Dermatology. 2014; 5 (16): 258-62. DOI: 10.3109/14764172.2014.948882.</mixed-citation><mixed-citation xml:lang="en">Cohen J. L. Scientific skepticism and new discoveries: an analysis of a report of zinc/phytase supplementation and the efficacy of botulinum toxins in treating cosmetic facial rhytides, hemifacial spasm and benign essential blepharospasm. Journal of cosmetic and laser therapy: official publication of the European Society for Laser Dermatology. 2014; 5 (16): 258-62. DOI: 10.3109/14764172.2014.948882.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Foster L., Foppiani J. A., Xun H., Lee D., Utz B., Hernandez Alvarez A., Domingo-Escobar M. J., Taritsa I. C., Gavlasova D., Lee T. C., Lin G. J., Choudry U., Lin S. J. Zinc in Dermatology: Exploring Its Emerging Role in Enhancing Botulinum Toxin Formulations and Clinical Efficacy. Curr Issues Mol Biol. 2024; 46 (11): 12088-12098. DOI: 10.3390/cimb46110717. PMID: 39590311; PMCID: PMC11593192.</mixed-citation><mixed-citation xml:lang="en">Foster L., Foppiani J. A., Xun H., Lee D., Utz B., Hernandez Alvarez A., Domingo-Escobar M. J., Taritsa I. C., Gavlasova D., Lee T. C., Lin G. J., Choudry U., Lin S. J. Zinc in Dermatology: Exploring Its Emerging Role in Enhancing Botulinum Toxin Formulations and Clinical Efficacy. Curr Issues Mol Biol. 2024; 46 (11): 12088-12098. DOI: 10.3390/cimb46110717. PMID: 39590311; PMCID: PMC11593192.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Kim D., Cho Y. B., Seo I. Botulinum Toxin Composition Having Prolonged Efficacy Duration. URL: https://patents.google.com/patent/US20210077596A1/en.</mixed-citation><mixed-citation xml:lang="en">Kim D., Cho Y. B., Seo I. Botulinum Toxin Composition Having Prolonged Efficacy Duration. URL: https://patents.google.com/patent/US20210077596A1/en.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Saravanakumar K., Park S., Santosh S. S., et al. Application of hyaluronic acid in tissue engineering, regenerative medicine, and nanomedicine: A review. Int J Biol Macromol. 2022; 222 (Pt B): 2744-2760. DOI: 10.1016/j.ijbiomac.2022.10.055.</mixed-citation><mixed-citation xml:lang="en">Saravanakumar K., Park S., Santosh S. S., et al. Application of hyaluronic acid in tissue engineering, regenerative medicine, and nanomedicine: A review. Int J Biol Macromol. 2022; 222 (Pt B): 2744-2760. DOI: 10.1016/j.ijbiomac.2022.10.055.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Selyanin M. A., Boykov P. Y., Khabarov V. N. Hyaluronic Acid: Preparation, Properties, Application in Biology and Medicine. Translated by Felix Polyak, 1st ed. Wiley. 2015. https://doi.org:10.1002/9781118695920.</mixed-citation><mixed-citation xml:lang="en">Selyanin M. A., Boykov P. Y., Khabarov V. N. Hyaluronic Acid: Preparation, Properties, Application in Biology and Medicine. Translated by Felix Polyak, 1st ed. Wiley. 2015. https://doi.org:10.1002/9781118695920.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Li L., Singh B. R. Role of zinc binding in type A botulinum neurotoxin light chain's toxic structure. Biochemistry. 2000; 34 (39): 10581-10586. DOI: 10.1021/bi0007472.</mixed-citation><mixed-citation xml:lang="en">Li L., Singh B. R. Role of zinc binding in type A botulinum neurotoxin light chain's toxic structure. Biochemistry. 2000; 34 (39): 10581-10586. DOI: 10.1021/bi0007472.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Fu F. N., et al. Role of zinc in the structure and toxic activity of botulinum neurotoxin. Biochemistry. 1998; 15 (37): 5267-78. DOI: 10.1021/bi9723966.</mixed-citation><mixed-citation xml:lang="en">Fu F. N., et al. Role of zinc in the structure and toxic activity of botulinum neurotoxin. Biochemistry. 1998; 15 (37): 5267-78. DOI: 10.1021/bi9723966.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Simpson L. L., et al. The role of zinc binding in the biological activity of botulinum toxin. The Journal of biological chemistry. 2001; 29 (276): 27034-27041. DOI: 10.1074/jbc.M102172200.</mixed-citation><mixed-citation xml:lang="en">Simpson L. L., et al. The role of zinc binding in the biological activity of botulinum toxin. The Journal of biological chemistry. 2001; 29 (276): 27034-27041. DOI: 10.1074/jbc.M102172200.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Elgend Y. S., et al. Effect of zinc or copper supplementation on the efficacy and sustainability of botulinum toxin A "Botox" injection in masseter muscle of albino rats. Journal of stomatology, oral and maxillofacial surgery. 2024; 5 (126): 102156. DOI: 10.1016/j.jormas.2024.102156.</mixed-citation><mixed-citation xml:lang="en">Elgend Y. S., et al. Effect of zinc or copper supplementation on the efficacy and sustainability of botulinum toxin A "Botox" injection in masseter muscle of albino rats. Journal of stomatology, oral and maxillofacial surgery. 2024; 5 (126): 102156. DOI: 10.1016/j.jormas.2024.102156.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Хатькова С. Е., Погорельцева О. А., Орлова О. Р. и др. Безопасность и эффективность применения препарата Релатокс в сравнении с препаратом Диспорт в лечении фокальной спастичности верхней конечности у пациентов после инсульта и черепно-мозговой травмы (результаты проспективного простого слепого рандомизированного сравнительного исследования в параллельных группах). Журнал неврологии и психиатрии им. С. С. Корсакова. 2024; 124 (12): 79-85.</mixed-citation><mixed-citation xml:lang="en">Khatkova S. E., Pogoreltseva O. A., Orlova O. R., et al. Safety and efficacy of Relatox in comparison with Dysport in the treatment of focal spasticity of the upper limb in patients after stroke and traumatic brain injury (results of a prospective simple blind randomized comparative study in parallel groups). Zhurnal nevrologii i psikhiatrii im. S. S. Korsakova. 2024; 124 (12): 79-85. (In Russ.) https://doi.org/10.17116/jnevro202412412179.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Гусев В. В., Макаров Е. А., Львова О. А. Сравнительный ретроспективный анализ эффективности препаратов ботулинического токсина типа А – гемагглютинин комплекса Релатокса и Ботокса в лечении пациентов с идиопатическим блефароспазмом. Журнал неврологии и психиатрии им. С. С. Корсакова. 2025; 125 (2): 86-90.</mixed-citation><mixed-citation xml:lang="en">Gusev V. V., Makarov E. A., Lvova O. A. Comparative analysis of the effectiveness of Botulinum toxin type A – hemagglutinin preparations of the Relatox and Botox complex in the treatment of patients with primary idiopathic blepharospasm. Zhurnal nevrologii i psikhiatrii im. S. S. Korsakova. 2025; 125 (2): 86 90. (In Russ.) https://doi.org/10.17116/jnevro202512502186.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Gusev V. V., Makarov E. A., Lvova O. A. Comparative analysis of the effectiveness of Botulinum toxin type A – hemagglutinin preparations of the Relatox and Botox complex in the treatment of patients with primary idiopathic blepharospasm. Zhurnal nevrologii i psikhiatrii im. S. S. Korsakova. 2025; 125 (2): 86-90. (In Russ.) https://doi.org/10.17116/jnevro202512502186.</mixed-citation><mixed-citation xml:lang="en">Gusev V. V., Makarov E. A., Lvova O. A. Comparative analysis of the effectiveness of Botulinum toxin type A – hemagglutinin preparations of the Relatox and Botox complex in the treatment of patients with primary idiopathic blepharospasm. Zhurnal nevrologii i psikhiatrii im. S. S. Korsakova. 2025; 125 (2): 86-90. (In Russ.) https://doi.org/10.17116/jnevro202512502186.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
